Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Organisation › Details

Activiomics Ltd.

Headquartered in London, UK, Activiomics Ltd. is a privately owned spin-out company from the Barts Cancer Institute (BCI), ranked one of the top five cancer research centres in the UK and a Queen Mary University of London campus. The company was founded in 2009 through investment from a number of sources including IP Group. Activiomics has developed a ground-breaking patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled. Activiomics' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of the proteome and of the phosphorylation status of cells and tissues. Phosphorylation is a critical mediator in all cellular processes and hence phosphorylated proteins represent an important class of novel biomarkers. Activiomics' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given cell or tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics. Activiomics is using exclusively accessed primary breast cancer samples to generate proof-of-concept data and high value data packages for novel predictive and prognostic markers of disease. Additionally, Activiomics commercialises its technology by partnering directly with large pharmaceutical and biotechnology companies in bespoke programmes of work. Recent partners include Genentech, UCB and GlaxoSmithKline. *

 

Period Start 2010-03-01 splitoff (date ca.)
  Group Retroscreen Virology (Group)
  Predecessor Queen Mary, University of London, Institute of Cancer
Products Industry mass spectrometry technology
  Industry 2 TIQUAS technology (Targeted In-depth Quantification of cell Signalling)
Persons Person FitzGerald, Kevin (Activiomics 201304– CEO F-Star 201104–201205 CEO LEFT 5/12 + Isogenica + CAT)
  Person 2 Warne, Mark (IP Group 201411 Healthcare Portfolio Director + Activiomics 201004 Interim CEO)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 24 Cornhill
  City EC3V 3ND London
  Tel +44-845-5195-091
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
  Currency GBP
  Profit -500,000 (2013-07-31)
     
    * Document for �About Section�: BioFocus. (9/19/13). "Press Release: Activiomics Extends Research Agreement with Kyowa Hakko Kirin as Part of Its Strategic Partnership with BioFocus".
     
   
Record changed: 2018-10-31

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Retroscreen Virology (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top